Cardiovascular Systems

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardiovascular Systems, Inc. (CSI) is devoted to developing and commercializing innovative solutions for treating peripheral and coronary vascular disease. Their primary focus is helping physicians conquer even the most difficult disease states, including calcium, given the complications. Cardiovascular Systems develop solutions for the treatment of peripheral and coronary artery disease, to help physicians conquer calcium, one of the largest challenges when treating PAD and CAD.

Cardiovascular Systems' (CSII) ECLIPSE clinical trial data is likely to help physicians form an optimal treatment plan for patients with severely calcified coronary arteries.

Cardiovascular Systems (CSII) Finishes ECLIPSE Trial Enrollment

ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC.

Cardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical Trial

Abbott Labs

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cardiovascular Systems, Inc. (“CSI”) (NasdaqGS: CSII) to Abbott Laboratories (NYSE: ABT). Under the terms of the proposed transaction, shareholders of CSI will receive $20.00 in cash for each share of CSI that they own.

CARDIOVASCULAR SYSTEMS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cardiovascular Systems, Inc. - CSII

Tough competition and consistent net loss continue to pose threats to Cardiovascular Systems (CSII).

Cardiovascular Systems (CSII) Ails From Soft Volume, Macro Woes

Abbott Laboratories expands its cardiovascular pipeline with the relatively small acquisition of Cardiovascular Systems, Inc. Cardiovascular Systems investors get a way out of a cash-burning stock at a decent price. The timing of the deal is opportunistic for Abbott.

Abbott Acquires Cardiovascular Systems: Key Takeaways For Investors

NEW YORK , Feb. 13, 2023 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Cardiovascular Systems, Inc. (NASDAQ: CSII), relating to its proposed sale to Abbott Laboratories. Under the terms of the agreement, CSII shareholders are expected to receive $20.00 in cash per common share they own.

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Cardiovascular Systems, Inc. - CSII

With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.

Cardiovascular Systems (CSII) Q2 Earnings, Revenues Miss

NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cardiovascular Systems, Inc. ("Cardiovascular Systems" or the "Company") (NASDAQ: CSII), in connection with the proposed acquisition of the Company by Abbott Laboratories (NYSE: ABT). Under the terms of the merger agreement, the Company's shareholders will receive $20.00 in cash for each share of Cardiovascular Systems owned.

SHAREHOLDER ALERT: Weiss Law Investigates Cardiovascular Systems, Inc.

Wilmington, Delaware--(Newsfile Corp. - February 9, 2023) - Rigrodsky Law, P.A. is investigating Cardiovascular Systems, Inc. ("Cardiovascular") (NASDAQ: CSII) regarding possible breaches of fiduciary duties and other violations of law related to Cardiovascular's agreement to be acquired by Abbott Laboratories. Under the terms of the agreement, Cardiovascular's shareholders will receive $20.00 per share in cash.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-cardiovascular-systems-inc.To contact Seth D. Rigrodsky or Gina M.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Cardiovascular Systems, Inc. Buyout

The medtech company has agreed to a buyout offer from Abbott Laboratories.

Why Cardiovascular Systems Stock Is Soaring Today

Cardiovascular Systems (NASDAQ: CSII ) stock is rising higher on Thursday following news that Abbott (NYSE: ABT ) intends to acquire the company. That deal has Abbott offering to buy Cardiovascular Systems for $890 million.

Why Is Cardiovascular Systems (CSII) Stock Up 48% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cardiovascular Systems, Inc. (NASDAQ: CSII) to Abbott Laboratories for $20.00 per common share is fair to Cardiovascular shareholders. Halper Sadeh encourages Cardiovascular shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

CSII STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Cardiovascular Systems, Inc. Is Fair to Shareholders

Cardiovascular Systems CSII, -1.99% shares rose 47% to $19.58 in early premarket trade after Abbott ABT, -1.60% agreed to buy the company for $890 million, or $20 per share. CSI is a leader in devices for atherectomy, a minimally invasive treatment for plaque build-up in arteries.

Cardiovascular Systems shares jump after deal to be bought by Abbott for $890 million

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -33.33% and 2.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022.

Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results

Cardiovascular Systems (CSII) international revenues are showing strong growth in each of the key markets, including Japan, Europe, Asia Pacific and Canada.

Cardiovascular Systems (CSII) Global Sales Up, Margin Woe Stays

ST. PAUL, Minn.--( BUSINESS WIRE )--Cardiovascular Systems, Inc. (NASDAQ: CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results.

Cardiovascular Systems, Inc. to Host Earnings Conference Call on February 9, 2023

ST. PAUL, Minn.--( BUSINESS WIRE )--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company has initiated the KAIZEN clinical study of its Diamondback 360© Peripheral Orbital Atherectomy System (OAS) for the treatment of calcified plaque in patients with peripheral artery disease (PAD). The study is intended to support regulatory approval in Japan.

Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical Study

ST. PAUL, Minn.--( BUSINESS WIRE )--Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that Innova Vascular, Inc. (Innova) has submitted a 510(k) Premarket Notification to the U.S. Food and Drug Administration (FDA) for its thrombectomy devices intended to treat peripheral vascular disease.

Cardiovascular Systems, Inc. Announces FDA 510(k) Submission of Innova Vascular, Inc.'s Thrombectomy System

The launch of the Scoreflex scoring balloon receives a positive response and generates over $1.7 million in sales during the first quarter for Cardiovascular Systems (CSII).

Cardiovascular Systems (CSII) Q1 Earnings Miss, Revenues Top

Cardiovascular Systems, Inc. to Participate in Two November Healthcare Conferences

Cardiovascular Systems, Inc. (NASDAQ:CSII ) Q1 2023 Results Conference Call November 3, 2022 9:00 AM ET Company Participants Jack Nielsen - Vice President of Investor Relations Scott Ward - Chairman, President and Chief Executive Officer Jeff Points - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Matson - Needham & Company Suraj Kalia - Oppenheimer Mathew Blackman - Stifel Jayson Bedford - Raymond James Operator Hello, everyone, and welcome to the Cardiovascular Systems, Inc., Fiscal 2023 First Quarter Earnings Conference Call. My name is Seth, and I'll be the operator for your call today [Operator Instructions].

Cardiovascular Systems, Inc. (CSII) Q1 2023 Earnings Call Transcript

Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -12.50% and 0.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems (CSII) Reports Q1 Loss, Tops Revenue Estimates

Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results

Cardiovascular Systems (CSII) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Cardiovascular Systems Stock (CSII)